首页|加巴喷丁联合微血管减压术治疗原发性三叉神经痛患者的效果

加巴喷丁联合微血管减压术治疗原发性三叉神经痛患者的效果

扫码查看
目的:观察加巴喷丁联合微血管减压术治疗原发性三叉神经痛患者的效果.方法:选取 2022 年 2 月至 2023 年 2 月该院收治的 82 例原发性三叉神经痛患者进行前瞻性研究,按照随机数字表法将其分为研究组和对照组各 41 例.对照组采用微血管减压术治疗,研究组在对照组基础上联合加巴喷丁治疗,比较两组临床疗效,治疗前后神经内分泌因子指标[降钙素基因相关肽(CGRP)、神经元特异性烯醇化酶(NSE)]水平、神经递质指标[β-内啡肽(β-EP)、5-羟色胺(5-HT)]水平,以及并发症/不良反应发生率和复发率.结果:研究组治疗总有效率为 95.12%(39/41),高于对照组的 78.05%(32/41),差异有统计学意义(P<0.05);治疗后,两组CGRP、NSE水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组β-EP、5-HT水平均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05);两组并发症/不良反应发生率比较,差异无统计学意义(P>0.05);研究组复发率低于对照组,差异有统计学意义(P<0.05).结论:加巴喷丁联合微血管减压治疗原发性三叉神经痛患者可提高治疗总有效率和神经递质指标水平,降低神经内分泌因子指标水平和复发率,其效果优于单纯微血管减压术治疗.
Effects of Gabapentin combined with microvascular decompression in treatment of patients with primary trigeminal neuralgia
Objective:To observe effects of Gabapentin combined with microvascular decompression in treatment of patients with primary trigeminal neuralgia.Methods:A prospective study was conducted on 82 patients with primary trigeminal neuralgia admitted to the hospital from February 2022 to February 2023.According to the random number table method,they were divided into study group and control group,41 cases in each group.The control group was treated with microvascular decompression,while the study group was treated with Gabapentin on the basis of that of the control group.The clinical efficacy,the levels of neuroendocrine factor indexes[calcitonin gene-related peptide(CGRP),neuron specific enolase(NSE)]and neurotransmitter indexes[β-endorphin(β-EP),5-hydroxytryptamine(5-HT)]before and after the treatment,and the incidence of complications/adverse reactions and recurrence rate were compared between the two groups.Results:The total effective rate of the study group was 95.12%(39/41),which was higher than 78.05%(32/41)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CGRP and NSE in the two groups were lower than those before the treatment,and those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of β-EP and 5-HT in the two groups were higher than those before the treatment,and those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of complications/adverse reactions between the two groups(P>0.05).The recurrence rate of the study group was lower than that of the control group,and the difference was statistically significant(P<0.05).Conclusions:Gabapentin combined with microvascular decompression in the treatment of the patients with primary trigeminal neuralgia can improve the total effective rate of treatment and the levels of neurotransmitter indexes,and reduce the levels of neuroendocrine factors and the recurrence rate.Moreover,it is superior to simple microvascular decompression treatment.

GabapentinMicrovascular decompressionPrimary trigeminal neuralgiaRecurrence rateNeuroendocrine factorNeurotransmitter

古瑞航、许耀伟、骆慧武

展开 >

洛阳市中医院神经外科,河南 洛阳 471000

加巴喷丁 微血管减压术 原发性三叉神经痛 复发率 神经内分泌因子 神经递质

2024

中国民康医学
中国社会工作协会

中国民康医学

影响因子:0.649
ISSN:1672-0369
年,卷(期):2024.36(16)
  • 13